Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LM 103

Next Previous
Drug Profile

LM 103

Alternative Names: Autologous tumour infiltrating lymphocytes - Suzhou BlueHorse Therapeutics; LM-103

Latest Information Update: 22 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou BlueHorse Therapeutics
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma; Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 02 Jun 2026 Efficacy, adverse event and pharmacodynamic data from phase I trial in Solid tumour presented at 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 22 Apr 2026 Updated efficacy, adverse events and pharmacodynamics data from a phase I trial in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
  • 26 Feb 2026 Phase-II clinical trials in Non-small cell lung cancer (Adjuvant therapy) in China (Parenteral) (NCT07444437)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top